Mechanism of cell death induced by cis-3, 4′, 5-trimethoxy-3′-aminostilbene in ovarian cancer

Gynecologic Oncology

Volumn 110, Issue 1, 2008, Pages 110-117

  Durrant, David ^a   Richards, Joanna E ^a   Walker, Winston T ^a   Baker, Kristen A ^a   Simoni, Daniele ^b   Lee, Ray M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cell cycle; Mitochondria; Ovarian cancer; Signal transduction; Stilbenes; Therapy

Indexed keywords

3,4,5 TRIMETHOXY 3 AMINOSTILBENE; ACETOACETIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BUB1 RELATED PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; COLCHICINE; COMBRETASTATIN A4; CYCLIN DEPENDENT KINASE 1; GG 251; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; STILBENE DERIVATIVE; VINCRISTINE;

ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CELL LYSATE; CELL STRAIN; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; FEMALE; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; STILBENES;

EID: 45549083444     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.031     Document Type: Article

References (45)

1. Jemal A., et al. Cancer statistics. 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Mano M.S., et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 17 2 (2007) 316-324
3. Jiang N., et al. Advances in mitotic inhibitors for cancer treatment. Mini Rev Med Chem 6 8 (2006) 885-895
4. Ravelli R.B., et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428 6979 (2004) 198-202
5. Pettit G.R., et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45 2 (1989) 209-211
6. Stevenson J.P., et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21 23 (2003) 4428-4438
7. Rustin G.J., et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21 15 (2003) 2815-2822
8. Beerepoot L.V., et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24 10 (2006) 1491-1498
9. Blakey D.C., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8 6 (2002) 1974-1983
10. Dowlati A., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62 12 (2002) 3408-3416
11. Pellegrini F., and Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23 3 (2005) 264-273
12. Stark G.R., and Taylor W.R. Control of the G2/M transition. Mol Biotechnol 32 3 (2006) 227-248
13. Izumi T., and Maller J.L. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell 4 12 (1993) 1337-1350
14. Lopez-Girona A., et al. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397 6715 (1999) 172-175
15. Blangy A., et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83 7 (1995) 1159-1169
16. Valentine M.T., Fordyce P.M., and Block S.M. Eg5 steps it up!. Cell Div 1 (2006) 31
17. Li W., et al. BUBR1 phosphorylation is regulated during mitotic checkpoint activation. Cell Growth Differ 10 11 (1999) 769-775
18. Chan G.K., et al. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol 146 5 (1999) 941-954
19. Gillett E.S., and Sorger P.K. Tracing the pathway of spindle assembly checkpoint signaling. Dev Cell 1 2 (2001) 162-164
20. Dowling M., et al. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 4 2 (2005) 197-206
21. Castedo M., et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 16 (2004) 2825-2837
22. Niida H., and Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 21 1 (2006) 3-9
23. Zhang S., Hemmerich P., and Grosse F. Centrosomal localization of DNA damage checkpoint proteins. J Cell Biochem 101 2 (2007) 451-465
24. Castedo M., et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23 25 (2004) 4353-4361
25. Roberti M., et al. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 46 16 (2003) 3546-3554
26. Cao, TM, et al., Stilbene derivatives that are colchicine site microtubule inhibitors have anti-leukemic activity and minimal systemic toxicity. Am J Hematol in press.
27. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat Med 6 5 (2000) 513-519
28. Desagher S., and Martinou J.C. Mitochondria as the central control point of apoptosis. Trends Cell Biol 10 9 (2000) 369-377
29. Harris M.H., et al. Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol 20 10 (2000) 3590-3596
30. Ricci J.E., et al. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 117 6 (2004) 773-786
31. Kowaltowski A.J., and Vercesi A.E. Reactive oxygen generation by mitochondria. In: Lemasters J.J., and Neiminen A. (Eds). Mitochondria in pathogenesis (2001), Kluwer Academic/Plenum Publishers, New York 281-300
32. Karimi M., et al. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 175 12 (2005) 7819-7828
33. Demasters G., et al. Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery. Mol Cancer Ther 5 11 (2006) 2786-2797
34. Loffler H., et al. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 5 21 (2006) 2543-2547
35. Kaneko Y.S., et al. Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene 18 25 (1999) 3673-3681
36. Zachos G., et al. Chk1 is required for spindle checkpoint function. Dev Cell 12 2 (2007) 247-260
37. Clark A.S., et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1 9 (2002) 707-717
38. Mabuchi S., et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277 36 (2002) 33490-33500
39. Blagosklonny M.V., et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56 8 (1996) 1851-1854
40. Kotha A., et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5 3 (2006) 621-629
41. Tang J., Erikson R.L., and Liu X. Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1). Proc Natl Acad Sci U S A 103 32 (2006) 11964-11969
42. Nabha S.M., et al. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8 8 (2002) 2735-2741
43. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 6 (2006) 1109-1122
44. Shaked Y., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 5794 (2006) 1785-1787
45. Durrant D, et al. cis-3, 4′, 5-trimethoxy-3′-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemother Pharmacol in press.